A Phase 1 interventional study of AGA2118 in Healthy Participants and Pharmacokinetic Study, sponsored by Angitia Incorporated Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Angitia Incorporated Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants
This Phase 1 ethnobriding study will evaluate the pharmacokinetics, pharmacodynamics, and safety of AGA2118 in Japanese, Chinese, and Caucasian participants. Participants will be administered AGA2118 at the start of the study and followed for 85 days.
Angitia Incorporated Limited is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of low dose AGA2118.
Drug: AGA2118
One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of medium dose AGA2118.
Drug: AGA2118
One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of high dose AGA2118.
Drug: AGA2118
Healthy Caucasian participants will receive a single administration of high dose AGA2118.
Drug: AGA2118
Healthy Chinese participants will receive a single administration of high dose AGA2118.
Drug: AGA2118
Participants will receive AGA2118 administered by subcutaneous injection
Maximum concentration (Cmax)
Cmax of AGA2118 after dosing
Time frame: Day 1 to up to the end of study (85 days post-dose)
Time to maximum concentration (Tmax)
Tmax of AGA2118 after dosing
Time frame: Day 1 to up to the end of study (85 days post-dose)
Area under the concentration-time curve (AUC)
AUC of AGA2118 after dosing
Time frame: Day 1 to up to the end of study (85 days post-dose)
Half-life (t1/2)
t1/2 of AGA2118 after dosing
Time frame: Day 1 to up to the end of study (85 days post-dose)
Clearance (CL)
CL of AGA2118 after dosing
Time frame: Day 1 to up to the end of study (85 days post-dose)
Volume of distribution (Vd)
Vd of AGA2118 after dosing
Time frame: Day 1 to up to the end of study (85 days post-dose)
Treatment-emergent adverse events (TEAEs)
Occurrence of TEAEs
Time frame: Baseline to the end of study (85 days post-dose)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Sep 2026, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AGA2118
Angitia Incorporated Limited